Thought Leadership

Recent Developments in Hepatitis C

  • Credit:1.0 ACCENT
  • Duration: 33 Minutes
  • Date:NOV.18.2014 12:00 AM - DEC.31.2015 12:00 AM

Price: $0.00

Member Price: $0.00

Description

Clinicians now have a wide variety of immunoassay and nucleic acid tests available to them to diagnose the many types of hepatitis viruses and manage the resulting infections, some of which are chronic and require lifelong management. Consequently, knowing which test to select in certain situations can be confusing. From test selection to result interpretation to monitoring therapy, lab leaders can play a much greater role in helping their institutions improve the processes that lead to earlier detection of the hepatitis viruses and better patient management. In the case of hepatitis C virus (HCV), new therapies are now available that are prolonging the lives of HCV patients, making it more important  than ever to identify and treat those with the disease. During this webcast, viewers will learn how lab leaders can help improve the processes used to identify and manage patients with hepatitis C infections, how to consult with cliniciansAnthony Killeen about what the results of hepatitis C and liver function tests mean clinically, partner with other healthcare providers to streamline testing and patient management protocols, and institute appropriate testing strategies for early detection.

Speaker Presentation Description 

Anthony Killeen, MD, PhD, Professor, Vice Chair for Clinical Affairs and Director of Clinical Pathology, University of Minnesota, Minneapolis, MN

Speaker Biography

Anthony Killeen, MD, PhD, is Professor, Vice Chair for Clinical Affairs, and Director of Clinical Pathology at the University of Minnesota in Minneapolis. Throughout his career, he has been involved in a number of professional societies, including the American Association for Clinical Chemistry, the Association for Molecular Pathology, and the College of American Pathologists. Dr. Killeen is a nationally recognized expert in clinical pathology. Prior to his current appointment, he served as director of clinical chemistry and molecular diagnostics at the University of Michigan Medical Center in Ann Arbor. He was also an advisor to the Michigan Governor’s Task Force on Genetic Privacy.

Dr. Killeen received his undergraduate and medical degrees from the National University of Ireland. He went on to receive his PhD in pathobiology from the University of Minnesota in Minneapolis. After an internship in internal medicine, he did a residency in laboratory medicine and pathology at the University of Minnesota, as well. He is certified by the American Board of Pathology in Clinical and Chemical Pathology, the American Board of Medical Genetics in Clinical Molecular Genetics, and the American Board for Clinical Chemistry in Molecular Diagnostics. He is licensed in Michigan and Minnesota.

Continuing Education

Obtain Your CE Here After Viewing the Program

By claiming continuing education credit for this activity, you are affirming that you have participated in this activity in its entirety.

Siemens 2014 logo

Sponsored By

Siemens 2014 logo

The AACC Thought Leadership Series is sponsored by AACC and the AACC Management Sciences and Patient Safety Division, and is made possible by a grant from Siemens Healthcare Diagnostics.